Monday, June 3
nucleic acids
8:00 AM – 8:45 AM Registration (at the registration desk in Portus Congress Center)
8:45 AM – 9:00 AM Organizing Committee Chair’s Opening Remarks (Djuro Josić)
Session Chairs: Ziad El Rassi (Oklahoma State University, USA) and Djuro Josić (University of Pula, Croatia)
9:00 AM – 9:35 AM Enabling CIMmultus DEAE columns at scale for plasmid DNA capture (Justina Martinkienė, Astra Zeneca)
9:35 AM – 10:00 AM High-quality, phase-appropriate plasmid manufacturing to accelerate advanced therapies (John Bowen, CBM)
10:00 AM – 10:25 AM High throughput manufacturing of personalized plasmid DNA cancer vaccines (Kathrin Seyrl, Biomay)
10:25 AM – 10:55 AM Coffee Break
Session Chairs: Zoltán Kis (University of Sheffield, UK) and Rok Sekirnik (Sartorius BIA Separations, Slovenia)
10:55 AM – 11:20 AM Sartorius In-Line Lysis System: Pioneering Success in Plasmid DNA Isolation (Matevž Korenč, Sartorius BIA Separations)
11:20 AM – 11:45 AM Debottlenecking vaccine manufacturing; effective supply of quality pDNA (Salomé de Sa Magalhaes, UCL)
11:45 AM – 12:10 PM Biotechnological platform to obtain a minicircle DNA vaccine targeting cervical cancer (Ângela Sousa, CICS-UBI) – Online
12:10 PM – 1:10 PM Lunch in the Congress Center (provided by the organizer)
Session Chairs: Sara Sousa Rosa (UCL, UK) and Dan Peer (NeoVac, UK)
1:10 PM – 1:45 PM Optimization of scalable lentiviral plasmid production for GMP manufacturing (Robert Rodick, VxBiosciences)
1:45 PM – 2:10 PM Novel, synthetic DNA templates for the production of mRNA (Carmen Mañas Torres, 4basebio)
2:10 PM – 2:35 PM Purification of linearized template plasmid DNA decreases double-stranded RNA formation during IVT reaction (Diego Casabona Agudo, Certest Biotec)
2:35 PM – 3:00 PM End-to-end solutions for IVT mRNA therapeutic development (Daniel Meng, VectorBuilder)
3:00 PM – 3:30 PM Coffee Break
Session Chairs: Salomé de Sa Magalhaes (UCL, UK) and Urh Černigoj (Sartorius BIA Separations, Slovenia)
3:30 PM – 3:55 PM Towards an efficient purification process for saRNA: exciting challenges and progress (Justine Jakpou, Ziphius Vaccines)
3:55 PM – 4:20 PM The many struggles and success of the establishing a pDNA manufacturing platform (Ahmet Hilmi Tekin, BioNTech)
4:20 PM – 4:45 PM mRNA vaccines: a perspective on process optimisation (Sara Sousa Rosa, UCL)
4:45 PM – 5:00 PM YRC: Development of immobilized enzyme reactors on monolith backbone for rapid plasmid DNA linearization (Maša Strašek, Sartorius BIA Separations)
5:00 PM – 5:15 PM YRC: Quality by design for mRNA platform purification based on continuous oligo-dT chromatography (Jixin Qu, University of Sheffield) – Online